DeciBio Launches Market Intelligence Portal With DeciChat, an AI Assistant Powered by DeciBio’s Proprietary Precision Medicine Research




DeciBio Launches Market Intelligence Portal With DeciChat, an AI Assistant Powered by DeciBio’s Proprietary Precision Medicine Research

DeciChat synthesizes thousands of data points across primary data sources to deliver deep insights into precision medicine markets instantly.

LOS ANGELES–(BUSINESS WIRE)–#ai–DeciBio Consulting (“DeciBio”), a precision medicine-focused strategy consulting and market intelligence firm, launched the DeciBio Market Intelligence Portal. The portal brings DeciBio’s Market Reports, DxBooks lab survey databases, Oncology Genomics Trackers, and Transcript Database into one subscription platform. It also introduces DeciChat, an AI assistant that performs cross-product querying and synthesis. Life science tools, diagnostics, and biopharma teams can ask a question and receive an answer drawn from across DeciBio’s research, with citations to the source data.

“Precision medicine is moving faster than traditional market research can track. And decisions that once took months of analysis now need to be made in weeks,” said Rebecca Burnham, PhD, Head of DeciBio’s Market Reports Division. “The Market Intelligence Portal and DeciChat give our clients direct access to the primary research that drives those decisions, in a form they can act on right away.”

DeciChat: One Question, Every Source

DeciChat helps teams get evidence-backed answers to the market questions behind their most important decisions, from sizing an opportunity to prioritizing markets or evaluating partners. Its AI agents search proprietary data from DeciBio’s precision medicine experts, then synthesize the findings into a single response. Each answer links back to the underlying report, dataset, or transcript, so teams can verify the numbers and insights and build on them in their own analyses.

“General-purpose AI tools are only as good as what they can find, and most precision medicine market data isn’t public,” said Andrew Stiegler, PhD, Head of DeciBio’s DxBooks Division. “DeciChat’s agents work directly on our private survey data, forecasts, and interview transcripts. Automated pipelines mean every new DxBook release, tracker update, and transcript is searchable as soon as the research is completed.”

What’s Included in the Market Intelligence Portal

The Market Intelligence Portal integrates DeciChat and all of DeciBio’s proprietary data products, including:

• Global Market Reports: Comprehensive market assessments with market sizing, segmentation, and 5-year forecasts, plus competitive analysis and assessments of key players, technologies, drivers, and moderators. Report topics span life science tools and diagnostics, including Digital & Computational Pathology, Oncology Liquid Biopsy, Next-Generation Sequencing, Spatial Biology, Single Cell Analysis, Proteomics Tools, Clinical Oncology Biomarker Testing, Blood-Based Testing in Neurodegenerative Diseases, Bioprocessing, Cell Therapy R&D and Manufacturing, Pharma Real-World Data & Evidence, and more.
• Snapshot Reports: Qualitative deep dives on emerging sub-segments, such as Pharma CDx Development & Commercialization, Biopharma’s Use of AI in Drug Discovery, and Precision Medicine Opportunities in Women’s Health.
• DxBooks: Databases built from annual surveys of clinical labs:
  • NGS DxBook: Panel testing, sample types, volumes, and reimbursement across 275 US and EU labs.
  • Infectious Disease DxBook: Testing settings, assays, and vendor selection for 30 analytes across 1,000 US clinical labs.
  • Digital Pathology DxBook: Scanner and IMS usage, algorithm integration, and vendor satisfaction across 400 US and EU labs.
• Oncology Genomics Trackers: Interactive dashboards tracking oncology genomic testing across 100 US labs (quarterly) and EU labs (semiannually), characterizing the use of genomic profiling, MRD / recurrence monitoring, and treatment response monitoring.
• Transcript Database: 450+ searchable expert interviews with stakeholders across large and small biopharma, academic medical centers, community hospitals, reference labs, CROs, and diagnostics companies.

New editions, data releases, and transcripts are added to the portal as they are published.

Availability

The DeciBio Market Intelligence Portal is available now through enterprise subscriptions to the full DeciBio Knowledgebase, custom packages built around an organization’s priority topics, or individual product subscriptions, with DeciChat available on any plan. Existing DxBooks and Oncology Genomics Trackers subscribers will be transitioned to the portal at no extra cost. The DeciBio Market Intelligence Portal is available now. Existing DxBook and Oncology Genomics Trackers subscribers will be moved to the Portal at no extra cost. To request a demo, visit www.decibio.com/intelligence-portal or contact rebecca.burnham@decibio.com.

About DeciBio

DeciBio Consulting is a precision medicine-focused strategy consulting and market intelligence firm whose mission is to accelerate the adoption of precision medicine. DeciBio helps leadership teams across therapeutics, diagnostics, research tools, and advanced manufacturing make strategy decisions grounded in scientific, technical, and execution reality. Its data division develops market intelligence software, databases, and reports covering life science research tools and diagnostics. DeciBio serves clients ranging from startups to Fortune 500 companies from offices in Los Angeles, New York City, Oakland, and London. Learn more at decibio.com.

Contacts

Media Contact
Rebecca Burnham

rebecca.burnham@decibio.com
310.451.4510

2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute




2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute

• University of Maryland School of Medicine will develop an AI-enabled screening platform to support earlier identification and referral of patients with ocular GVHD.
• H. Lee Moffitt Cancer Center & Research Institute plans to advance understanding of the unique challenges and support needs of caregivers for people living with chronic GVHD.

WILMINGTON, Del.–(BUSINESS WIRE)–Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers.

“It is our honor to recognize the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute as recipients of the 2026 Incyte Ingenuity Awards in GVHD,” said Mohamed Issa, Executive Vice President and Head of U.S. Commercial, Incyte. “Their innovative projects address critical needs within the GVHD community, from enabling earlier identification and referral of patients with ocular GVHD to deepening our understanding of the unique challenges faced by caregivers. GVHD can profoundly impact both patients and those who care for them, and these community-driven initiatives have the potential to make a meaningful difference in the lives of those affected.”

The University of Maryland School of Medicine designed its project, Ocular Surface Imaging Guidance and Health Triage (OSIGHT), to improve the early identification of ocular GVHD by developing and evaluating an AI-enabled screening platform for use in transplant clinics. The tool will identify patients at risk and facilitate timely referrals to ophthalmology specialists. By integrating ocular imaging, clinical measurements and patient-reported symptoms, the project seeks to support earlier detection, improve care coordination and preserve vision and quality of life for people living with GVHD.

The H. Lee Moffitt Cancer Center & Research Institute’s project, Understanding the Needs of Caregivers Caring for Those with Chronic GVHD, recognizes the important role caregivers play in GVHD care. The initiative seeks to address the lack of research and support resources available to caregivers, an often-overlooked population within the GVHD community. Through in-depth interviews, the initiative will identify GVHD caregivers’ unique challenges, stressors and support needs. Insights from the study will be disseminated broadly and help inform the development of future caregiver-focused support programs tailored to improve the well-being of those caring for someone with GVHD.

Applications for the 2026 Incyte Ingenuity Awards in GVHD were evaluated by an independent judging panel consisting of GVHD community experts and advocates, including:

• Hugo Fernandez, MD, Chair and Medical Director, Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Professor of Oncology, University of South Florida Morsani College of Medicine
• Christina Ferraro, CNP, Outpatient Advanced Practice Provider Manager, Director of Survivorship, Transplantation and Cellular Therapy and Apheresis, Cleveland Clinic Cancer Institute
• Kathleen D. Lyons, ScD, OTR/L, Occupational Therapist, Professor of Occupational Therapy, Mass General Brigham University of Health Professions, Director, Cancer Rehabilitation (CaRe) Lab, MGH Institute
• Lynne Spina, Director of Development and Marketing, BMT InfoNet

To maintain the integrity of the judging process, any judge affiliated with an applying organization was precluded from the review of that organization’s application.

Read more about these winning initiatives and the Incyte Ingenuity Awards in GVHD at https://www.incyteingenuityawards.com/gvhd/.

About GVHD

Graft-versus-host disease (GVHD) is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor) in which the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant. Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) tract and liver.¹

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Contacts

Media
media@incyte.com

Investors
ir@incyte.com

Phillips Medisize Acquires Chippenham Facility to Expand Global Inhalation Center of Excellence




Phillips Medisize Acquires Chippenham Facility to Expand Global Inhalation Center of Excellence

• The investment strengthens the company’s Global Inhalation Center of Excellence that also includes a dedicated facility in Cambridge.
• Building on the 2025 acquisition of Vectura Group Ltd., which added critical inhalation capabilities to the company’s existing suite of drug delivery devices, this Chippenham expansion enables Phillips Medisize to leverage its global footprint to accelerate innovation and significantly grow its inhalation revenue.
• Pharmaceutical customers addressing complex conditions such as Pulmonary Arterial Hypertension (PAH), along with non-respiratory diseases affecting millions worldwide, rely on the company’s extensive inhalation combination product development expertise and its ability to scale device manufacturing globally.

CHIPPENHAM, England & HUDSON, Wis.–(BUSINESS WIRE)–#Biologics—Phillips Medisize, a Molex company and a leader in the design, development, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, today announced an investment to acquire the complete footprint of its Chippenham site. Together with its Cambridge location, the newly acquired facility strengthens the company’s Global Inhalation Center of Excellence (COE) and provides additional capacity to support projected business growth.

Following the acquisition of Vectura Group Ltd., the combined capabilities are driving growth as expanded inhalation expertise and Phillips Medisize’s global footprint create new opportunities to innovate, scale and serve customers. The Chippenham footprint of 58,963 square meters (about 634,670 square feet) on approximately 3.41 acres provides Phillips Medisize with long-term operational control to broaden drug-device combination product formulation development for both early and late-phase clinical trial supplies manufacturing. This acquisition supports an anticipated growing pipeline of complex inhaled small molecule and biologic therapies. Industry data from AlphaSense indicates the market for inhalation and nasal drug delivery devices is experiencing robust growth. This expansion is driven by broadening respiratory drug pipelines and a structural shift toward outsourcing the development of complex combination products.

“With our inhalation revenue projected to grow substantially over the next five years, securing this full site ensures we have the dedicated talent, laboratories and cleanroom capacity required to support pharmaceutical companies from early-stage feasibility all the way through commercial scale-up,” said Charlie Schumacher, vice president of inhalation therapies at Phillips Medisize. “Since the Vectura acquisition, we are tracking ahead of schedule on our growth model and are confident in our trajectory. This expansion in Chippenham reinforces our momentum and ensures proven technical expertise and manufacturing continuity for our customers worldwide.”

The combined Chippenham and Cambridge locations serve as the company’s dedicated Global Inhalation COE. Across both facilities, Phillips Medisize provides end-to-end combination product development and manufacturing capabilities for small molecules, biologics and generic products.

“We are deeply grateful for the overwhelming support and positive reception we continue to receive from our customers and the broader respiratory industry following the Vectura acquisition,” said Sandy Munro, chief inhalation scientist at Phillips Medisize. “Our team is absolutely delighted to be where we should be, back at industry conferences and on the podium sharing our latest research. We remain deeply committed to advancing the science in our field to bring more effective inhalation therapies to patients across the world, including those dealing with complex and challenging diseases like Pulmonary Arterial Hypertension (PAH).”

The Global Inhalation COE supports all major inhalation formats, including dry powder inhalers (DPIs) and nebulizers. These device platforms are backed by comprehensive pharmaceutical development services encompassing powder and liquid formulation expertise. This includes advanced particle engineering via spray drying and powder blending at a broad range of scale, alongside full analytical testing, technical transfer and clinical trial supply manufacturing.

Beyond the inhalation COE, Phillips Medisize offers customers a fully integrated global network featuring 30 locations across North America, Europe and Asia, with 23 production facilities and seven R&D innovation centers. Having supported more than 200 product launches and 150 drug delivery programs over the past five years, Phillips Medisize provides the proven capability required to bring complex therapies from development to commercialization.

About Phillips Medisize

Phillips Medisize, a Molex company, collaborates with leading pharmaceutical, medical technology and in vitro diagnostic companies to design, engineer and manufacture lifesaving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to collaborate with customers to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives. For more information, visit www.phillipsmedisize.com.

About Molex

Molex is a global electronics leader committed to making the world a better, more-connected place. With a presence in more than 40 countries, Molex enables transformative technology innovation in the consumer device, aerospace and defense, data center, cloud, telecommunications, transportation, industrial automation and healthcare industries. Through trusted customer and industry relationships, unrivaled engineering expertise and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life. For more information, visit www.molex.com.

Contacts

Media Contact:
M+

Healthcare Marketing & Communications

Paula Moggio

Paula@mplushealth.com

Amphista Therapeutics to Present AMX-883 Data at American Society of Hematology (ASH) Annual Meeting




Amphista Therapeutics to Present AMX-883 Data at American Society of Hematology (ASH) Annual Meeting

• AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia (AML)
• Additional abstract on AMX-883 BRAMLIE trial assessing safety, pharmacokinetics, and preliminary efficiency to publish in Blood

CAMBRIDGE, England–(BUSINESS WIRE)–Amphista Therapeutics Limited (‘Amphista’ or ‘the Company’), a clinical-stage biopharmaceutical company focused on the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced new data on its lead therapeutic candidate, AMX-883, has been accepted for oral presentation at American Society of Hematology (ASH) Annual Meeting in New Orleans, December 12–15, 2026. The full abstract is available online: www.hematology.org/Meetings/Annual-Meeting/Abstracts

The data, to be presented by Dr Louise Modis, CEO, suggest BRD9 plays a critical role in acute myeloid leukemia (AML), maintaining activity of a number of hematopoietic transcription factors. Degradation of BRD9 using AMX-883 restricts these transcription factor programs, releasing the differentiation block and reducing the frequency of leukemic stem cells.

Presentation details:

• Title: AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia
• Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Cell-Intrinsic and Niche-Mediated Mechanisms of Drug Resistance in AML. December 14, 2026, 10:30 AM – 12:00 PM
• Room: MCCNO – Great Hall BC
• Presentation time: December 14, 2026, 11:45 AM – 12:00 PM
• Publication number: 762
• Submission ID: abs26-9908

The second abstract, due to be published in the ASH Blood Supplement, highlights Amphista’s ongoing AMX-883 BRAMLIE trial (1), an open label, multi-part, dose escalation and optimization study:

• Abstract number: abs26-2088
• Title: A Phase 1, open-label, multi-centre study to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukemia and high-risk myelodysplastic syndrome and in combination in participants with AML
• Category: 600s – Hematologic Malignancy
• Review category: 616. Acute Myeloid Leukemias: lnvestigational Drug and Cellular Therapies
• Authors: Eytan Stein, Emma Searle, Amir Fathi, Jayastu Senapati, Justin Watts, Victoria Campbell, Jenny O’Nions, Alexander Spira, David Taussig, Paul Player, Giulia Petrone, Anthony Selwyn Stein, Lisa Butler, Patrick Kelly
  

1. https://amphista.com/amphista-therapeutics-announces-first-patient-dosed-in-amx-883-phase-1-clinical-trial-for-acute-myeloid-leukemia/

Contacts

Media contact:
Lorna Cuddon

Zyme Communications

Tel: +44(0)7811 996 942

Email: lorna.cuddon@zymecommunications.com

Iksuda to Present First Clinical Data for IKS03 in Advanced B-Cell Non-Hodgkin Lymphomas at ASH




Iksuda to Present First Clinical Data for IKS03 in Advanced B-Cell Non-Hodgkin Lymphomas at ASH

Impressive early anti-tumour activity and a therapy-leading safety profile seen in heavily pretreated patients across multiple B-cell lymphoma subtypes

Objective response rate of 53% in 17 efficacy evaluable patients, including responses in patients previously treated with CD19-directed CAR-T cell therapy

NEWCASTLE, England–(BUSINESS WIRE)–Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of preliminary data from the dose escalation portion of its Phase 1 study of IKS03, a CD19-directed ADC, in patients with advanced B-cell non-Hodgkin lymphoma (B-NHL), at the 68th American Society of Hematology (ASH) Annual Meeting, December 12–15, 2026, New Orleans, Louisiana.

As of 8 July 2026, 21 patients (median age 67 years) with a median of four prior lines of therapy (range 2-8) have been treated with IKS03 across five dose levels up to 3.1 mg/m² (approximately 84µg/kg). A maximum tolerated dose (MTD) has not been reached.

IKS03 showed a highly differentiated and manageable safety profile, with treatment-related adverse events (TRAEs) affecting only seven of 21 patients. Compared with other treatments across modalities, there was a markedly lower frequency of high-grade neutropenia and thrombocytopenia and an absence of peripheral neuropathy. A single Grade 4 neutropenia (4.8%), a dose-limiting toxicity, was observed in the fourth dose cohort in a patient with follicular lymphoma and bone marrow involvement, and who had previously received six prior regimens including CAR-T. On resolution, the patient remained on therapy and in response. There were only two Grade 3 neutropenia events, and all remaining TRAEs were mild or moderate (Grade 1–2). No patient experienced a Grade 5 event or a treatment-related serious adverse event, and none stopped treatment because of an adverse event. Non-haematological toxicity was both limited and low-grade.

Responses to treatment were observed from the lowest dose level (around 20 µg/kg) and across all dose cohorts. Of 17 patients evaluable for efficacy (those who had completed two treatment cycles across the first four dose levels), nine responded, giving an overall objective response rate (ORR) of 53%, with two patients achieving stable disease. Five patients (29%) achieved a complete metabolic response: two with follicular lymphoma and one each with diffuse large B-cell lymphoma, marginal zone lymphoma and T cell/histiocyte-rich large B-cell lymphoma. Four patients (24%) achieved a partial metabolic response, two each with follicular lymphoma and marginal zone lymphoma.

Responses were seen in patients who were CAR-T naïve, as well as in those who had received prior CAR-T (3 of 4 patients), including a durable complete response in a patient who had received 8 prior regimens which included failed responses to CAR-T and allogeneic transplantation. Of the eight patients who did not respond, five were being treated for Richter-transformed diffuse large B-cell lymphoma, well known to be highly aggressive and difficult to treat.

Responses have lasted up to 14 months. Currently, six of the nine responders eligible for efficacy assessment at the time of writing remain on treatment. Dose escalation is ongoing and updated results will be presented at the convention.

Dr. Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, commented: “These first clinical data for IKS03 are incredibly exciting. To see responses in patients treated from the lowest dose level and across all cohorts, in heavily pretreated patients including those who had previously received CD19-directed CAR-T therapy, is immensely rewarding, whilst the safety profile is distinct from all other therapies in use for these cancers. These results support the design strategy of tumour-selective payload release, and we look forward to onward progression of this exciting program.”

Prof. Enrico Derenzini, European Institute of Oncology IRCCS, Milan, added: “Patients with relapsed or refractory B-cell lymphoma who have already received several lines of treatment have limited options. To see responses at this early stage, alongside a manageable safety profile, is encouraging and supports further evaluation of IKS03.”

The Phase 1 study (NCT05365659) is a first-in-human, multicentre trial of IKS03 in patients with relapsed or refractory B-NHL who have received at least two prior systemic therapies. Part I (dose escalation) uses a 3+3 design to determine the MTD and recommended Phase 2 dose in patients with CD19-positive follicular, marginal zone, mantle cell, large B-cell (including Richter-transformed) or high-grade B-cell lymphoma. Part II will assess efficacy in disease-specific expansion cohorts. Around 140 patients are expected to be enrolled across the study.

Presentation details

Abstract number: 5456

Title: First-in-human phase 1 trial to determine safety and preliminary antineoplastic activity of IKS03, a CD19-targeting PBD prodrug antibody drug conjugate, in advanced B-cell non-Hodgkin lymphomas

Presenter: Prof. Enrico Derenzini

Session Name: 629. Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies: Poster III

Session Date: December 14, 2026

Session Time: 12/14/2026 6:00:00 PM – 12/14/2026 8:00:00 PM

Presentation Time: 12/14/2026 6:00:00 PM – 12/14/2026 8:00:00 PM

Room: MCCNO – Hall F

About IKS03

IKS03 is a best-in-class CD19-targeting ADC delivering a tumour-activated prodrug pyrrolobenzodiazepine (PBD) which was licensed from LigaChem Biosciences (formerly LegoChem Biosciences). Preclinical testing demonstrated best-in-class efficacy (vs in-clinic and marketed CD19-targeted therapies) in in vivo xenograft models and significantly raised maximum tolerated dose (MTD) in non-human primate disease models, demonstrating its potential to be the leading anti-CD19 therapy in B-cell cancers.

About Iksuda Therapeutics: www.iksuda.com

Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading ADCs targeting difficult-to-treat haematological and solid tumours. Iksuda’s pipeline of ADCs is centred on a portfolio of prodrug ADCs which utilise tumour-selective release and activation of payloads, incorporating proprietary and in-licensed (from LigaChem Biosciences) prodrug and linker technologies in combination with stable conjugation chemistries including its proprietary PermaLink® platform. The early pipeline incorporates Iksuda’s proprietary, first-in-class protein alkylating payload class, ‘ProAlk™. The Company’s design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer.

Contacts

Iksuda Therapeutics
Dave Simpson, Chief Executive Officer

Tel: +44 (0) 191 6031680

info@iksuda.com

FTI Consulting (Financial Media and IR)

Simon Conway / Natalie Garland Collins / Amy Byrne

Tel: +44 (0) 020 3727 1000

Iksuda@fticonsulting.com

Innate Pharma Reports Third Quarter 2026 Business and Financial Update




Innate Pharma Reports Third Quarter 2026 Business and Financial Update

• Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event

• Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in Sézary syndrome in H2 2027

• AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027

• Cash position of €96.8 million¹ as of September 30, 2026; anticipated cash horizon until the end of Q1 2028

• Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET

MARSEILLE, France–(BUSINESS WIRE)–$IPH #ADC–Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine months ended September 30, 2026.

“As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic priorities,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “We look forward to presenting Phase 1 dose-escalation data from IPH4502, our differentiated Nectin-4 ADC, on November 18, while actively preparing for first patient dosing in the Phase 3 TELLOMAK-3 study of lacutamab in Q1 2027. We also look forward to the readout of the AstraZeneca-led PACIFIC-9 Phase 3 trial, which includes monalizumab and is now expected in the first half of 2027.”

Pipeline highlights

IPH4502 (Nectin-4 exatecan ADC):

• IPH4502 is Innate Pharma’s proprietary Nectin-4-targeting ADC, combining a differentiated antibody, a proprietary stable linker and an exatecan payload, with the potential to overcome Enfortumab Vedotin (EV) resistance in urothelial carcinoma (UC) and target tumors with low or heterogeneous Nectin-4 expression beyond UC. IPH4502 is currently being evaluated in a Phase 1 trial in advanced solid tumors known to express Nectin-4 (IPH4502-101; NCT06781983).
• As announced in July 2026 (Link PR), enrollment in the Phase 1 dose-escalation of the IPH4502-101 study is complete, with 76 patients enrolled across multiple solid tumor types.
• Phase 1 dose-escalation data will be presented as a poster at the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, on November 18, 2026 (Barcelona).
• Following the ENA presentation, Innate Pharma will host a hybrid event focused on IPH4502 on November 18, 2026, at 4:00 pm GMT (11:00 am ET) with in-person attendance in London at the IET London, Savoy Place and a live webcast accessible here.

Lacutamab (anti-KIR3DL2 antibody), developed in collaboration with Sobi:

• As announced on August 10, 2026 (Link PR), Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma.
• Following closing of the transaction, Innate is advancing TELLOMAK-3, the confirmatory Phase 3 study of lacutamab in Cutaneous T Cell Lymphoma (CTCL), with first patient dosing expected in Q1 2027.
• Phase 3 TELLOMAK-3 includes a confirmatory cohort in Sézary syndrome and a registrational cohort in Mycosis Fungoides.
• Innate plans an FDA filing in H2 2027 for accelerated approval in Sézary syndrome based on the existing Phase 2 TELLOMAK data once the confirmatory Phase 3 study is underway (Link PR).

Monalizumab (anti-NKG2A antibody), developed in collaboration with AstraZeneca:

• Enrollment is complete in the AstraZeneca-sponsored Phase 3 PACIFIC-9 study evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III NSCLC who have not progressed following platinum-based chemoradiation therapy.
• As announced on October 27 (Link PR), AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study.

Corporate update

• Frédéric Lombard, Chief Financial Officer, will step down from his position on December 31, 2026, to pursue new career opportunities. The Company thanks him for his contributions and dedication during his time with the Company. The Company has initiated a search of potential candidates to replace Mr. Lombard.
• As of September 30, 2026, the balance available under our April 2023 sales agreement under the At-The-Market program remains at $75 million.

Financial highlights for Q3 2026

Cash, cash equivalents and financial assets of the Company amounted to €96.8 million as of September 30, 2026, which includes the $75 million upfront payment resulting from the closing of the Sobi transaction and the aggregate gross proceeds from the €30 million private placement offering of ordinary shares that occurred in August 2026. Also as of September 30, 2026, financial liabilities amounted to €16.2 million.

Revenues for the first nine months of 2026 amounted to €3.4 million (€2.3 million for the same period in 2025). Revenue from collaboration and licensing agreements mainly results from the partial or entire recognition of the proceeds received pursuant to the co-development and license agreements with AstraZeneca and research collaboration and license agreements with Sanofi.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

Stéphanie Cornen

VP, Investor Relations & Corporate Communications

stephanie.cornen@innate-pharma.fr

Investor Relations

investors@innate-pharma.fr

Media

communication@innate-pharma.fr

World-First Achievement: SUSMED’s Blockchain-Based Clinical Trial System Supports Successful Marketing Authorization for Pharmaceutical Product




World-First Achievement: SUSMED’s Blockchain-Based Clinical Trial System Supports Successful Marketing Authorization for Pharmaceutical Product

– Pioneering Solutions for Drug Lag and Loss –

TOKYO–(BUSINESS WIRE)–SUSMED, Inc. (TOKYO:4263) announced that “SUSMED SourceDataSync®” (“SUSMED SDS”), its proprietary blockchain-based clinical trial system, has contributed to obtaining marketing authorization for a pharmaceutical product^1,2,3.

This marks the world’s first pharmaceutical approval based on the results of an industry-sponsored clinical trial utilizing blockchain technology⁴.

Challenges in Pharmaceutical Development

Global research and development (R&D) expenditure for pharmaceuticals continues to rise, increasing at an annual rate of approximately 8.5% over the past decade⁵. Key drivers of the rise in R&D expenditure include advancement of R&D and the increasing complexity of protocols. In Japan, both labor-intensive and over-engineering practices intended to comply with the Good Clinical Practice(GCP) ordinance have been widely highlighted as major contributing factors. It also results in the fact that the number of clinical trial sites managed per Clinical Research Associate (CRA) in Japan is only one-third of that in the United States⁶. Consequently, rising development costs lead to serious drug lag and drug loss, which in turn is posing significant challenges to social and economic securities.

In recent years, the updated international guideline for Good Clinical Practice, ICH-E6(R3), outlined the Quality by Design (QbD) approach. The guideline states that the sponsor should avoid unnecessary complexity and not place unnecessary burden on participants and investigators. Implementing an appropriate system to manage quality throughout all stages of the trial process is also required.

Our Solution and Initiatives

SUSMED SDS is a clinical trial management system that utilizes blockchain technology to securely syncronize medical data captured at medical institutions with Case Report Form (CRF) data. This enables a significant reduction in both data entry workload at medical sites and regulatory-mandated monitoring tasks. The verification results in the Regulatory Sandbox system were published in a peer-reviewed international medical journal in June 2020 (Hirano et al., 2020, JMIR). Based on these findings, SUSMED submitted an application under the “System of Inquiry on Regulatory Gray-Zone Areas” pursuant to the Industrial Competitiveness Enhancement Act and, on December 4, 2020, the Ministry of Health, Labour and Welfare (MHLW) issued an official notification⁷ confirming that substituting monitoring tasks with blockchain technology is compliant with Japan’s GCP ordinance.

Furthermore, a comparative evaluation between conventional clinical trial workflows and the SUSMED SDS workflow, conducted under the Research and Development Promotion Network Project supported by the Japan Agency for Medical Research and Development (AMED), demonstrated that monitoring workload decreased by 45.9%, medical institution workload decreased by 32.0%, and data queries for verification and correction decreased by 46.7%⁸. These findings indicate that, while substantially reducing overall operational overhead, the use of blockchain technology for clinical trial data management contributes significantly to streamlining processes, improving productivity in alignment with Quality by Design (QbD) principles.

Additionally, GAMP 5 Second Edition, the GxP guidance published by the International Society for Pharmaceutical Engineering (ISPE) in 2022, highlighted blockchain technology as a key solution for enhancing data integrity, which signals growing global expectations for the expanded use of blockchain across the clinical trial ecosystem.

Achievements and Future Outlook

The regulatory approval of a pharmaceutical product based on a clinical trial utilizing blockchain technology marks the world-first achievement, driving expectations for the broader implementation of this technology to accelerate the establishment of a modern clinical trial ecosystem.

Comment from Taro Ueno, President and CEO of SUSMED, Inc.:

“I, as a clinician, believe that the issue of Drug Loss, where pharmaceuticals used for patient care overseas remain unavailable in Japan, is a critical challenge.

In 2020, through our participation in the Regulatory Sandbox system and System of Inquiry on Regulatory Gray-Zone Areas under the Industrial Competitiveness Enhancement Act, we demonstrated that utilizing blockchain technology enables efficient compliance with the GCP ordinance.

I am deeply moved that marketing approval has now been granted for a pharmaceutical product based on this deregulation, and that is opening the door to delivering new treatment options to patients. I extend my heartiest gratitude to all stakeholders whose dedicated efforts made this milestone possible.

SUSMED remains committed to contributing to the optimal development of new therapies through the advancement of establishment of an innovative clinical trial ecosystem.”

In addition, Hirohiko Nakahara, Secretary-General, Secretariat of Intellectual Property Strategy Headquarters, Cabinet Office (former Counsellor, Economic Revitalization Bureau, Cabinet Secretariat), and Kazumi Nishikawa, Deputy Director-General, Minister’s Secretariat, Ministry of Economy, Trade and Industry (former Director, Healthcare Industries Division, Ministry of Economy, Trade and Industry), sent us the following comments:

Comment from Mr. Hirohiko Nakagawa, Secretary-General, Secretariat of Intellectual Property Strategy Headquarters, Cabinet Office:

“I would like to offer my sincere congratulations on the marketing approval granted by the Ministry of Health, Labour and Welfare for a pharmaceutical product validated through blockchain-based clinical trial system. It is profoundly meaningful that this approval was achieved based on the results obtained through the Regulatory Sandbox system. We look forward to seeing innovative technologies and solutions continue to contribute to resolving societal challenges in the future.

Comment from Mr. Kazumi Nishikawa, Deputy Director-General, Minister’s Secretariat, Ministry of Economy, Trade and Industry:

“I am delighted to see SUSMED’s initiative progressing appropriately as an effort leading the improvement of healthcare quality through the application of technology, as well as a concrete successful example of utilizing the Regulatory Sandbox system. I look forward to their further endeavors toward achieving a ‘Well Aging Society’ in the future.”

This world-first achievement, wherein regulatory marketing approval was granted for a pharmaceutical validated through a clinical trial leveraging blockchain technology following deregulation, represents a major step forward in addressing the challenges such as drug lag and drug loss. We have built a solid track record of reducing both costs and operational workload in clinical development through the utilization of SUSMED SDS, and we look forward to expanding its implementation among a broader range of clinical trials of pharmaceutical companies. Furthermore, by contributing to the establishment of a clinical trial ecosystem anchored in QbD principles, we aim to enhance productivity and quality in drug development, ultimately to support the optimization and long-term sustainability of future social security expenditures.

Reference Material

Key Implementation Examples of SUSMED SDS

• Industry-sponsored clinical trials^9,10 not only for pharmaceuticals, but also for medical devices and regenerative medicine products.

• A wide spectrum of clinical research¹¹, including specified clinical research and investigator initiated trials¹² for prescription digital therapeutics (PDTx).
• A disease registry¹³ designed to support post-marketing database studies aimed at leveraging Real-World Data (RWD), expected to facilitate efficient data collection, enhance the value of post-marketing surveillance, and promote the strategic utilization of clinical data for label expansions and the development of proper-use guidelines.

New Technology Demonstration system (The Regulatory Sandbox system)

The “New Technology Demonstration system” (commonly known as the Regulatory Sandbox system) was established under the Act on Special Measures for Productivity Improvement to promote business activities utilizing novel technologies and innovative business models. By limiting participants and timeframes, this framework creates a controlled environment that allows companies to conduct real-world demonstrations without being bound by existing regulations. This system enables rapid verification, and allows to leverage the resulting data and evidence to drive regulatory reform.

About SUSMED, Inc.

SUSMED, Inc. is a R&D driven enterprise dedicated to advancing digital healthcare. In addition to developing digital therapeutics (DTx), including a therapeutic application for insomnia disorder. SUSMED provides a clinical development support system powered by blockchain technology. Grounded in robust technology, SUSMED is driving the evolution of digital healthcare through a proprietary intellectual property portfolio covering various patents in digital therapeutics and medical applications of blockchain technology.

Top page: https://www.susmed.co.jp/en/
SUSMED SDS: https://www.susmed.co.jp/en/system/

Notes

The information regarding pharmaceutical products contained in this release is intended solely for corporate disclosure purposes and does not constitute an advertisement or promotion of them.

Contacts

SUSMED, Inc.

E-mail: support@susmed.co.jp

E.SUN Debuts at COP17, Showcasing Taiwan’s Nature Finance in Action




E.SUN Debuts at COP17, Showcasing Taiwan’s Nature Finance in Action

TAIPEI, Taiwan–(BUSINESS WIRE)–E.SUN Financial Holding made its debut at the 17th Conference of the Parties to the Convention on Biological Diversity (CBD COP17), bringing Taiwan’s nature finance experience to the global stage. E.SUN Chief Sustainability Officer Louis L.Y. Chang was invited by the World Climate Foundation (WCF) and the Finance for Biodiversity Foundation (FfB) to speak in the Blue Zone on October 26 and 27 about “Bridging the Biodiversity Financing Gap: E.SUN’s Practice and Vision for Nature Capital.”

Held in Yerevan, Armenia, from October 19 to 30 under the theme “Taking Action for Nature,” CBD COP17 reviewed progress on the Kunming-Montreal Global Biodiversity Framework and explored ways to accelerate action and mobilize finance for nature. As the only Taiwanese financial institution attending COP17, E.SUN shared how financial institutions can connect finance, businesses, and local communities to advance biodiversity. Based on E.SUN’s keynote, representatives from UNEP FI, the Inter-American Development Bank, Danske Bank Asset Management and Storebrand Asset Management further elaborated the discussion on strengthening stakeholder collaboration, supporting business transition, and scaling biodiversity finance.

E.SUN’s biodiversity efforts span conservation, education, and culture. Since 2014, E.SUN’s Malavi Project has supported Indigenous farmers in adopting organic farming practices, with more than 19 hectares of farmland now organically certified. In 2026, the project became one of Taiwan’s first certified Other Effective Area-Based Conservation Measures (OECMs), demonstrating how agricultural production and conservation can mutually reinforce one another.

In 2022, E.SUN partnered with National Taiwan University to launch the ESG Centenary Project, which aims to plant 100,000 native Taiwanese conifers over ten years. The partnership also revived 28 indigenous millet varieties in Xinyi Township, Nantou County, contributing to both native plant conservation and Indigenous cultural preservation.

E.SUN also uses finance to translate biodiversity ambitions into business action. Its “Farm to Table Sustainable Food and Agriculture Value Chain Financing” initiative connects agriculture, food processing, logistics, hospitality and other industries to support sustainable food systems. E.SUN has also established biodiversity and OECM-linked loans with Yulon Motor and CPC Corporation, Taiwan, incorporating species restoration and habitat conservation into financing arrangements.

Through a Public-Private-Philanthropic Partnership (PPPP), E.SUN has further brought together Okuma Fishing Tackle, the Kaohsiung Wild Bird Society, the Kaohsiung City Government Tourism Bureau, and Taiwan Water Corporation to remove invasive species and restore habitats at Niaosong Wetland through Nature-based Solutions.

“Without nature and biodiversity, climate action cannot succeed,” said Chang. “Finance can serve as a bridge between conservation and development, between local action and global impact, and between today’s investment and a nature-positive future.”

E.SUN will continue to harness the positive impact of finance and cross-sector collaboration to mobilize capital, expertise, and talent for nature-positive action, while bringing Taiwan’s experience in connecting finance, business, communities, and conservation to the global stage. ***

Contacts

Public Relations, E.SUN FHC

Virginia Lin

pr@esunfhc.com
(+8862)2175-1335

Public Relations, E.SUN FHC

Alice Chen

pr@esunfhc.com
(+8862)2175-1313 #8190

Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals




Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals

– Oral, highly selective and potent VAV1 molecular glue degrader designed to deliver a differentiated clinical profile across a broad range of indications in autoimmune disease

– Phase 1 expected to begin imminently; Evommune plans to initiate a Phase 2 trial in rheumatoid arthritis in 2027

– Evommune to pay $20MM upfront in cash and $10MM in the form of pre-funded warrants and up to approximately $1.1B in development, regulatory and commercial milestones, plus tiered royalties

PALO ALTO, Calif. & NEW YORK & CHENGDU, China–(BUSINESS WIRE)–Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, and Hinova Pharmaceuticals Inc. (SSE: 688302) today announced an exclusive license agreement granting Evommune worldwide rights outside of Greater China to develop, manufacture and commercialize EVO570 (formerly HC118 and known as HP570 in Greater China), an oral VAV1-directed molecular glue degrader (MGD).

VAV1 is a signaling protein that prominently drives T- and B-cell activation across a wide range of chronic inflammatory diseases. EVO570, discovered by Hinova, is an investigational oral MGD designed to selectively eliminate VAV1, quieting the immune activity underlying many autoimmune diseases. Unlike JAK enzymes, which are broadly expressed across many tissues and organs, VAV1 is largely restricted to immune cells, a core rationale for its potential to offer a much-needed, favorable safety and tolerability profile. In preclinical studies, EVO570 has demonstrated promising activity in animal models of multiple immune-mediated conditions and greater potency in human immune cells than competitor VAV1 degraders. Investigational New Drug (IND) applications have been submitted in China and accepted in the United States, and a Phase 1 trial evaluating safety, pharmacokinetics and target engagement/pharmacodynamics is on track to begin imminently.

“VAV1 is a compelling target in immunology today, offering a potential path to JAK-like efficacy without the safety and tolerability challenges of other available therapies,” said Dr. Jeegar Patel, Chief Scientific Officer of Evommune. “With a differentiated scaffold and structure-guided optimization resulting in sub-nanomolar potency, high selectivity and a profile supporting once-daily oral dosing, EVO570 has the potential to be a best-in-class approach for patients with rheumatoid arthritis and other T- and B-cell-driven autoimmune diseases. We look forward to reporting Phase 1 results and plan to advance it into its first Phase 2 trial in rheumatoid arthritis in 2027.”

“Adding this development-stage program is a strategic step for Evommune, expanding our pipeline into T- and B-cell-driven autoimmune diseases with a differentiated oral degrader that complements our existing pipeline,” said Greg Moss, Chief Business and Legal Officer of Evommune. “We have been impressed by Hinova’s innovative drug discovery and execution capabilities, and we are pleased to partner with a team that shares our commitment to developing differentiated therapies for patients. With this transaction, we are adding a novel therapeutic candidate with wide-ranging potential, while maintaining a disciplined portfolio management approach, and continuing to position Evommune to create meaningful long-term value for patients with chronic inflammatory diseases and for our stockholders.”

“We are proud to partner with Evommune, a leading immunology company with a proven track record of advancing differentiated therapies for chronic inflammatory diseases,” said Dr. Yuanwei Chen, Founder and Chairman of Hinova. “EVO570’s advancement reflects the strength of Hinova’s targeted protein degrader and translational medicine platforms, and we believe Evommune’s development expertise and global reach make it the ideal collaborator to bring this potential best-in-class VAV1 degrader to patients worldwide.”

Terms of the agreement

As consideration for the license, Evommune will pay Hinova $30 million upfront, consisting of $20 million in cash and $10 million in the form of pre-funded warrants to purchase Evommune common stock. Hinova is eligible to receive up to approximately $1.1 billion in development, regulatory and commercial milestones, as well as tiered royalties on net sales outside Greater China. BFC Group served as exclusive financial advisor and Fangda Partners served as exclusive legal advisor to Hinova.

About VAV1 and EVO570

VAV1 is a guanine nucleotide exchange factor largely restricted to immune cells that transmits signals from the T-cell and B-cell receptors to drive activation, cytokine production and migration. EVO570 is an orally administered MGD that directs VAV1 to the cell’s protein-disposal machinery for degradation. EVO570 is an investigational drug candidate and has not yet been approved by any regulatory authority.

About Evommune

Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn.

About Hinova

Hinova Pharmaceuticals Inc. (SSE: 688302), headquartered in Chengdu, China, is an international, clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative therapies for treating cancer, autoimmune diseases and metabolic diseases. Hinova has one product that has been approved in China for prostate cancer. The company’s pipeline includes multiple investigational drugs, including traditional small molecules, deuterated drug, PROTAC degraders, molecular glue degrader, targeting a variety of cancer types, autoimmune diseases and metabolic disorders, all aimed at addressing significant unmet medical needs and improving patient outcomes.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements.” These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit and best-in-class potential of EVO570, including the safety and tolerability profile of EVO570; the anticipated benefits of the license agreement with Hinova, including Evommune’s expectations regarding its worldwide rights (outside of Greater China) to develop, manufacture and commercialize EVO570; the design, objectives, initiation, timing and progress of the planned Phase 1 trial and the planned global Phase 2 trial of EVO570 in rheumatoid arthritis expected to begin in 2027; the timing and amount of upfront, milestone and royalty payments payable to Hinova under the license agreement, and Evommune’s ability to achieve the development, regulatory and commercial milestones that would trigger such payments; the Company’s ability to create meaningful long-term value for patients with chronic inflammatory diseases and for its stockholders; and the Company’s business strategies, plans and prospect and continued advancement of the Company’s portfolio. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates, including EVO570; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the anticipated benefits of the license agreement with Hinova and its other collaborations and license agreements, and to achieve the milestones and make the related payments contemplated by such agreements; changes in expected or existing competition; changes in the regulatory environment, including with respect to products licensed from and regulatory applications pending in China; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K, filed with the SEC on March 5, 2026, as supplemented by the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 6, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Contacts

Evommune Media and Investors: Megan Humphreys, megan.humphreys@evommune.com

Hinova: Investor Relations: ir@hinovapharma.com

Evommune Announces $30 Million Private Placement




Evommune Announces $30 Million Private Placement

PALO ALTO, Calif. & NEW YORK–(BUSINESS WIRE)–Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,966,889 shares of its common stock to a select group of dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $6.04. Evommune anticipates the gross proceeds from the private placement to be approximately $30 million, before deducting any transaction-related expenses. The private placement is expected to close on or about November 6, 2026, subject to the satisfaction of customary closing conditions.

The financing includes participation from both new and existing institutional investors, including Adage Capital Partners, L.P., Balyasny Asset Management, Defilade Capital Management, OrbiMed, Squadron Capital Management and other fundamental healthcare dedicated funds.

Morgan Stanley & Co. LLC and Leerink Partners LLC acted as placement agents for the private placement. Oppenheimer & Co. Inc. acted as capital markets advisor for the private placement.

Evommune intends to use the net proceeds from the private placement to advance its clinical development programs, including EVO570, its newly in-licensed oral VAV1-directed molecular glue degrader, and for general corporate purposes.

The offer and sale of the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Concurrently with entering into the securities purchase agreement, Evommune and the investors entered into a registration rights agreement pursuant to which Evommune has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Evommune, Inc.

Evommune, Inc., is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements.” These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning expected proceeds from the private placement, expected use of proceeds, and expected closing of the private placement. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 6, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Contacts

Investors and Media:
Megan Humphreys

megan.humphreys@evommune.com